BR112023004179A2 - Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmo - Google Patents
Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmoInfo
- Publication number
- BR112023004179A2 BR112023004179A2 BR112023004179A BR112023004179A BR112023004179A2 BR 112023004179 A2 BR112023004179 A2 BR 112023004179A2 BR 112023004179 A BR112023004179 A BR 112023004179A BR 112023004179 A BR112023004179 A BR 112023004179A BR 112023004179 A2 BR112023004179 A2 BR 112023004179A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- same
- pyrimid
- pyrimidinone compound
- pyrimidinone
- Prior art date
Links
- -1 PYRIMIDINONE COMPOUND Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 title abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSTO DE PIRIMIDO PIRIMIDINONA E COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO. A presente invenção refere-se a um composto de pirimido pirimidinona tendo um efeito de inibição da expressão de PD-L1 e uma composição farmacêutica compreendendo o mesmo como um ingrediente ativo. O composto de pirimido pirimidinona pode ser usado de maneira eficaz para o tratamento ou a prevenção do câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200119100 | 2020-09-16 | ||
| PCT/KR2021/012616 WO2022060094A1 (ko) | 2020-09-16 | 2021-09-15 | 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023004179A2 true BR112023004179A2 (pt) | 2023-04-11 |
Family
ID=80777269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023004179A BR112023004179A2 (pt) | 2020-09-16 | 2021-09-15 | Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmo |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230348474A1 (pt) |
| EP (1) | EP4215533A1 (pt) |
| JP (1) | JP2023541052A (pt) |
| CN (1) | CN116137815A (pt) |
| AU (1) | AU2021344164A1 (pt) |
| BR (1) | BR112023004179A2 (pt) |
| CA (1) | CA3190461A1 (pt) |
| IL (1) | IL300920A (pt) |
| MX (1) | MX2023003087A (pt) |
| WO (1) | WO2022060094A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0413005A (pt) | 2003-07-29 | 2006-09-26 | Irm Llc | compostos e composições como inibidores da proteìna cinase |
| US7655651B2 (en) * | 2004-08-31 | 2010-02-02 | Hoffmann-La Roche Inc. | Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| GB201315072D0 (en) * | 2013-08-23 | 2013-10-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders |
| US10954242B2 (en) * | 2016-07-05 | 2021-03-23 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
-
2021
- 2021-09-15 JP JP2023515773A patent/JP2023541052A/ja active Pending
- 2021-09-15 WO PCT/KR2021/012616 patent/WO2022060094A1/ko active Application Filing
- 2021-09-15 US US18/245,395 patent/US20230348474A1/en active Pending
- 2021-09-15 EP EP21869716.7A patent/EP4215533A1/en active Pending
- 2021-09-15 BR BR112023004179A patent/BR112023004179A2/pt unknown
- 2021-09-15 CN CN202180063334.1A patent/CN116137815A/zh active Pending
- 2021-09-15 AU AU2021344164A patent/AU2021344164A1/en active Pending
- 2021-09-15 CA CA3190461A patent/CA3190461A1/en active Pending
- 2021-09-15 IL IL300920A patent/IL300920A/en unknown
- 2021-09-15 MX MX2023003087A patent/MX2023003087A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230348474A1 (en) | 2023-11-02 |
| IL300920A (en) | 2023-04-01 |
| AU2021344164A9 (en) | 2024-03-21 |
| MX2023003087A (es) | 2023-04-14 |
| KR20220036895A (ko) | 2022-03-23 |
| WO2022060094A1 (ko) | 2022-03-24 |
| AU2021344164A1 (en) | 2023-05-04 |
| CN116137815A (zh) | 2023-05-19 |
| EP4215533A1 (en) | 2023-07-26 |
| CA3190461A1 (en) | 2022-03-24 |
| JP2023541052A (ja) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018004175B8 (pt) | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto | |
| EP4360713A3 (en) | Quinazoline derivatives as antitumor agents | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| BR112019024264A2 (pt) | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer | |
| BR112023015067A2 (pt) | Composto de quinazolina para induzir a degradação de proteína kras g12d mutante | |
| JOP20220163A1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| BR112023022451A2 (pt) | Composto triazina substituído | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112022000251A2 (pt) | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 | |
| BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
| MX2022005749A (es) | Inhibidores de egfr alostericos y metodos de uso de los mismos. | |
| BR112020020708A8 (pt) | Derivados da ureia cíclica fundidã como antagonista crhr2 | |
| MX2021008667A (es) | Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo. | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| BR112013024909A2 (pt) | composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| MX2022015739A (es) | Inhibidores alostericos de egfr y metodos de uso de estos. | |
| BR112023004179A2 (pt) | Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmo | |
| BR112021017829A2 (pt) | Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer |